Cas:442903-28-8 Methyl 2,4-dichloronicotinate manufacturer & supplier

Chemical Name:Methyl 2,4-dichloronicotinate

CAS.NO:442903-28-8

Synonyms:3-Pyridinecarboxylic acid, 2,4-dichloro-, methyl ester;2,4-Dichloro-3-(methoxycarbonyl)pyridine;Methyl2,4-Dichloronicotinate;Methyl 2,4-dichloronicotinate

Molecular Formula:C₇H₅Cl₂NO₂

Molecular Weight:206.026

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:266.2±35.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.548

PSA:39.19000

Exact Mass:204.969727

LogP:1.39

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Pyridinecarboxylic acid, 2,4-dichloro-, methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl 2,4-dichloronicotinate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-Dichloro-3-(methoxycarbonyl)pyridine Use and application,Methyl 2,4-dichloronicotinate technical grade,usp/ep/jp grade.

Related News: Speaking to Sky News, Raab said he could not confirm the ��precise number�� of those arriving into the UK on Sunday. Methyl 2,4-dichloronicotinate manufacturer Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs. Methyl 2,4-dichloronicotinate supplier The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. Methyl 2,4-dichloronicotinate vendor Speaking to Sky News, Raab said he could not confirm the ��precise number�� of those arriving into the UK on Sunday. Methyl 2,4-dichloronicotinate factory Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.